July 20, 2024
Ursodeoxycholic acid

Market Opportunity In Rising Gallstones Cases Is Anticipated To Openup The New Avenue For Ursodeoxycholic Acid Market

Ursodeoxycholic acid or UDCA is a bile acid produed naturally in the liver. It is used to treat liver diseases like primary biliary cholangitis (PBC) and gallstones. Ursodeoxycholic acid works by making bile less harmful to the liver and can help dissolve some gallstones. It comes in capsule form to be taken orally. The key uses of UDCA include treatment of gallstones, primary biliary cirrhosis and prevention of liver transplant rejection.

The Ursodeoxycholic Acid Market is estimated to be valued at US$ 640.45 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The Ursodeoxycholic Acid market is primarily driven by rising prevalence of gallbladder and liver disorders globally. Gallbladder diseases affect around 25 million Americans annually. Gallstones which is a common gallbladder disorder could affect up to 25% of the American population over their lifetime according to reports. This widespread occurrence of gallstones is expected to upsurge the demand for ursodeoxycholic acid significantly.

Another major factor propelling the market growth is increasing applications of UDCA in treatment of various liver diseases. Ursodeoxycholic acid is now approved for treatment of primary biliary cholangitis (PBC) which is a progressive liver disease that destroys bile ducts in the liver. As per estimations, around 100,000 Americans suffer from PBC making it a major application area. Moreover, research studies exploring potential of UDCA in nonalcoholic fatty liver disease (NAFLD) and liver transplants are anticipated to further augment the adoption.

Segment Analysis:

The ursodeoxycholic acid market is divided into two dominant segments – pharma grade and tech grade. The pharma grade segment accounts for over 70% of the total market share owing to increasing use of ursodeoxycholic acid in liver disease treatment, gallstone dissolution, and other therapeutic areas. This segment is dominating due to strong demand for Ursodeoxycholic acid in pharmaceutical formulations.

PEST Analysis:

Political: The growth of the ursodeoxycholic acid market is favorably impacted by supportive regulatory policies and guidelines by regulatory bodies like FDA for use of UDCA in treatment of various diseases.

Economic: The rising incidence of liver diseases and increasing healthcare spending is fueling the economic growth of this market. Also, growing generics market provides scope for low-cost treatment options.

Social: Changing lifestyle habits leading to obesity, excessive alcohol consumption are propelling the cases of non-alcoholic fatty liver disease (NAFLD) and other chronic liver disorders. This is generating high social demand for effective treatment therapies.

Technological: Advancements in drug delivery technologies help in developing novel formulations like capsules, injectables using ursodeoxycholic acid for improved treatment efficacy and patient compliance.

Key Takeaways:

The Global Ursodeoxycholic Acid Market Demand is expected to witness high growth at a CAGR of 10% over the forecast period of 2023 to 2030. The market is estimated to reach a value of over US$ 1,125 Mn by 2030 due to increasing prevalence of chronic liver diseases.

Regionally, North America leads with over 30% revenue share owing to rising fatty liver disease burden coupled with availability of advanced healthcare facilities. Asia Pacific exhibits highest growth and is projected to grow at a CAGR of 12% during the forecast period. This is attributed to growing medical tourism, rapidly developing pharmaceutical industry and increasing obesity in China and India.

Key players operating in the Ursodeoxycholic Acid market are PharmaZell, ABIL CHEMPHARMA PRIVATE LIMITED, ICE, Grindeks, Suzhou Tianlu Bio-pharmaceutical Co.,Ltd, ARCELOR CHEMICALS PRIVATE LIMITED, Dipharma Francis S.r.l. PharmaZell dominates with over 20% market share on back of wide product portfolio and global market reach. ABIL CHEMPHARMA PRIVATE LIMITED is another leading player owing to strong presence in generic UDCA formulations across European and Asia Pacific regions.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it